Sélectionner une page


a company at the crossroads
of Biotechnology and Molecular
Biology innovations

Save millions of lives

by delivering diagnostic
results in 3 hours

Detect and identify 99%

of sepsis pathogens at species level
with revolutionary sensitivity

Sepsis in numbers

49 M

people affected annually1

Targeted specific microbial therapy shall be engaged within first hours, whereas blood cultures deliver results in 1-10 days6




in the US2


 in France3


billions in UK4

49 M

annually affected people1


billions in US2


billions in France3


billions in UK4



Targeted specific microbial therapy shall be engaged within first hours, whereas blood culture deliver results in 1-10 days6

1. World Health Organization https://www.who.int/sepsis/en/
2. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013 (MAY 2016) HCUP Statistical Brief #204
3. https://www.senat.fr/rap/r05-421/r05-42113.html

4. https://healthcare-in-europe.com/en/news/sepsis.html
5. Riou et al. Int. J Technol. Assess. Health Care 2006;22:101-108
6. Zielgler et al., J. Clin. Microbiol. 1998;36:657-61

our solution

OCEAN offers a patented multiplexing molecular diagnostics kit.

  99% sepsis pathogen identification (all Gram positive and Gram negative bacteria)

Results in less than 3 hours

Revolutionary sensitivity of 0.3 cell/ml of blood

 Drop mortality from 35% to 5 %, saving millions of lives worldwide

Healthcare cost reduction

Better antimicrobial management, avoiding drug resistance


OCEAN Dx wins i-Lab 2020 prize

OCEAN Dx wins i-Lab 2020 prize

The Start-up OCEAN Dx, specialised in  infectious diseases in vitro diagnostic (Bordeaux, France), won the i-Lab 2020 contest organized by the French Ministry of Higher Education, Research, and Innovation. The 250 000 € prize will enable OCEAN Dx to complete its...

lire plus

OCEAN Dx is an In Vitro Diagnostic company.
Our goal is to offer revolutionary diagnostic tests for infectious diseases.



11 Avenue de Canteranne
Bâtiment PLEIONE
33600 Pessac FRANCE